Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAF(V600E) melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Zhang, Gao, Frederick, Dennie T., Wu, Lawrence, Wei, Zhi, Krepler, Clemens, Srinivasan, Satish, Chae, Young Chan, Xu, Xiaowei, Choi, Harry, Dimwamwa, Elaida, Ope, Omotayo, Shannan, Batool, Basu, Devraj, Zhang, Dongmei, Guha, Manti, Xiao, Min, Randell, Sergio, Sproesser, Katrin, Xu, Wei, Liu, Jephrey, Karakousis, Giorgos C., Schuchter, Lynn M., Gangadhar, Tara C., Amaravadi, Ravi K., Gu, Mengnan, Xu, Caiyue, Ghosh, Abheek, Xu, Weiting, Tian, Tian, Zhang, Jie, Zha, Shijie, Liu, Qin, Brafford, Patricia, Weeraratna, Ashani, Davies, Michael A., Wargo, Jennifer A., Avadhani, Narayan G., Lu, Yiling, Mills, Gordon B., Altieri, Dario C., Flaherty, Keith T., Herlyn, Meenhard
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855947/
https://ncbi.nlm.nih.gov/pubmed/27043285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI82661
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados